Sirnaomics Ltd. is an international biopharmaceutical company that engages in developing and commercializing of RNAi technology and multiple therapeutics. Its lead clinical drug candidates include STP705 and STP707. It is capitalizing on its dual delivery platforms, which include Polypeptide nanoparticle (PNP) and GalAhead. The company was founded by Yang Lu in 2007 and is headquartered in Hong Kong.